Valstar

• Antineoplastic Agents
• ATC:L01DB09

• Antibiotic Ad 32
• Valrubicin [Usan]
• Valstar
• Valstar Preservative Free

• No information avaliable

C₃₄H₃₆F₃NO₁₃

http://www.rxlist.com/cgi/generic2/rubicin.htm

Valstar FDA

No information avaliable

723.644 g/mol

116-117^oC

insoluble

Solid

3.332

Liquid

Bladder cancer

When 800 mg Valstar was administered intravesically to patients with carcinoma in situ, Valstar penetrated into the bladder wall. The mean total anthracycline concentration measured in bladder tissue exceeded the levels causing 90% cytoxicity to human bladder cells cultured in vitro. During the two-hour dose-retention period, the metabolism of Valstar to its major metabolites N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol was neglible. After retention, the drug was almost completely excreted by voiding the instillate. Mean percent recovery of Valstar, N-trifluoroacetyladriamycin, and total anthracyclines in 14 urine samples from six patients was 98.6%, 0.4%, and 99.0% of the total administered drug, respectively. During the two-hour dose-retention period, only nanogram quantities of Valstar were absorbed into the plasma.

No information avaliable

No information avaliable

Humans and other mammals